ALNY Price Prediction Next Week
Technical Analysis
Based on recent price action and technical indicators, ALNY shows a mixed technical picture. The stock has formed a consolidation pattern after its Q4 earnings beat. The strong earnings results, with EPS of $0.06 versus expected -$0.60, provide fundamental support for potential upward movement.
Price Targets & Analyst Views Recent analyst coverage shows mixed sentiment:
- Needham maintains Buy rating with $320 target
- Canaccord raised target to $385 from $384
- Scotiabank lowered target to $300 from $310
Catalysts & News Impact
- Upcoming Research and Development Day on February 25
- Strong Q4 performance with 35% YoY revenue growth to $593.2M
- Product revenue growth of 30.2% to $450.8M
- Operating loss of $105M due to increased R&D spending
Price Prediction for Next Week Based on technical analysis and recent catalysts:
- Support level: $145
- Resistance level: $165
- Most likely scenario: Range-bound trading between $150-$160
Target prices:
- Bullish case: $165 (30% probability)
- Base case: $155 (50% probability)
- Bearish case: $145 (20% probability)
Trading Recommendation: HOLD Current technical setup suggests range-bound trading. While fundamentals remain strong with impressive Q4 results, increased R&D spending and mixed analyst views warrant caution. Better entry points may emerge after the upcoming R&D Day event provides more clarity on pipeline developments.
ALNY Similar Chart Price Prediction
The price of ALNY is predicted to go up 2.59%, based on the high correlation periods with CPBI. The similarity of these two price pattern on the periods is 97.67%.
ALNY
CPBI
Up: 2.59%Similarity: 97.67%
ALNY Revenue Forecast
ALNY EPS Forecast
ALNY FAQs
What is bull’s view on ALNY?
What is bear's view on ALNY?
What is ALNY revenue forecast for next quarter？
ALNY VS S&P500
Alnylam's Nobel-prize-winning technology and massive intellectual property in RNA interference helped the firm create an entirely new class of therapeutics for difficult to treat diseases.
Alnylam's full pipeline offers several opportunities to bolster the company's competitive position, and it indicates a reproducible research strategy.
Onpattro is the first approved RNA interference therapy. In addition to first-mover advantage, Alnylam is positioned to expand its reach in ATTR amyloidosis with next-generation Amvuttra, which is administered less frequently.
ALNY Analyst's Forecast
Greg Harrison
Scotiabank
Buy
2025-02-14
Price Target
$310 → $300
Upside
+17.82%
Scotiabank lowered the firm's price target on Alnylam to $300 from $310 and keeps an Outperform rating on the shares. The firm is encouraged by the company's Q4 results, which were marked by consistent revenue growth, the analyst tells investors. The firm expects the company to continue to execute on clinical, regulatory, and commercial fronts, which should drive the company to sustainable profitability by year end.
William Pickering
Bernstein
Buy
2025-01-07
Price Target
$314 → $310
Upside
+31.51%
Andy Chen
Wolfe Research
Hold → Sell
2024-11-12
Price Target
n/a
Downside
0%
